GSK.L - GlaxoSmithKline plc

LSE - LSE Delayed price. Currency in GBp
1,555.00
-3.20 (-0.21%)
As of 8:31AM BST. Market open.
Stock chart is not supported by your current browser
Previous close1,558.20
Open1,556.00
Bid1,555.00 x 175400
Ask1,555.20 x 417900
Day's range1,553.20 - 1,560.20
52-week range1,236.40 - 1,632.00
Volume413,676
Avg. volume9,481,751
Market cap76.404B
Beta1.00
PE ratio (TTM)74.40
EPS (TTM)20.90
Earnings date25 Jul 2018
Forward dividend & yield0.80 (5.17%)
Ex-dividend date2018-05-10
1y target est1,587.62
  • 4 Biggest HIV Drugs of 2024: Which Stocks Are Poised to Profit?
    Motley Fool20 hours ago

    4 Biggest HIV Drugs of 2024: Which Stocks Are Poised to Profit?

    A game of musical chairs is coming to the HIV market.

  • FTSE 100 recovers, driven by defensives, as trade nerves ebb
    Reuters5 days ago

    FTSE 100 recovers, driven by defensives, as trade nerves ebb

    By Helen Reid LONDON (Reuters) - British shares bounced back on Thursday, driven by financial and consumer stocks, as investor worries eased and another bid for pay-TV firm Sky boosted its stock. The FTSE ...

  • Reuters - UK Focus5 days ago

    FTSE 100 recovers, driven by defensives, as trade nerves ebb

    British shares bounced back on Thursday, driven by financial and consumer stocks, as investor worries eased and another bid for pay-TV firm Sky boosted its stock. The FTSE 100 ended the session up 0.8 ...

  • Pfizer (PFE) to Reorganize Business Into Three New Units
    Zacks5 days ago

    Pfizer (PFE) to Reorganize Business Into Three New Units

    Pfizer (PFE) is re-organizing its business into three business segments, effective 2019. It is separating its consumer healthcare business into a standalone unit.

  • GlaxoSmithKline Stock’s June Performance
    Market Realist11 days ago

    GlaxoSmithKline Stock’s June Performance

    British multinational pharmaceutical company GlaxoSmithKline (GSK) divides its business into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. As it is a British company, it reports its revenue in British pounds. The chart below shows GlaxoSmithKline’s revenue and EPS since Q1 2017, and analysts’ estimate for Q2 2018.

  • How Novartis’s Valuation Compares
    Market Realist12 days ago

    How Novartis’s Valuation Compares

    Healthcare giant Novartis (NVS) researches, develops, manufactures, and commercializes pharmaceutical products. Novartis surpassed analysts’ revenue and EPS estimates during Q1 2018, with its revenue growing 4% year-over-year to $12.7 billion from $11.5 billion at constant exchange rates. Foreign exchange boosted its revenue by 6%.

  • Analysts’ Estimates and Recommendations for GSK in June
    Market Realist12 days ago

    Analysts’ Estimates and Recommendations for GSK in June

    Analysts expect GlaxoSmithKline (GSK) to report revenue of ~7.1 billion British pounds during the second quarter, a 2.3% fall in year-over-year revenue compared to ~7.3 billion pounds during the second quarter of 2017. The company’s EPS are expected to be 25.96 pence during the second quarter.

  • Reuters - UK Focus12 days ago

    FOCUS-Drugmakers try evasion, tougher negotiations to fight new U.S. insurer tactic

    In the escalating battle over U.S. prescription drug prices, major pharmaceutical companies are scrambling to limit the economic damage from a new U.S. insurer tactic that coaxes patients away from expensive drugs. The latest move by insurers - which effectively forces drug companies to pay more to assist patients with their copays - is causing a decline in real U.S. drug prices this year, and is expected to become more widely adopted in 2019. Among major drugmakers, AbbVie Inc (LSE: 0QCV.L - news) and Amgen Inc (NasdaqGS: AMGN - news) have said the most so far about the new tactic, and more drugmakers will likely face questions about it during quarterly earnings calls in July.

  • The Quarterly Performance of GSK’s Vaccines Segment
    Market Realist13 days ago

    The Quarterly Performance of GSK’s Vaccines Segment

    GlaxoSmithKline’s (GSK) Vaccines segment includes influenza vaccines, meningitis vaccines, Shingles vaccines, and established vaccines. The segment reported a 7% rise in YoY (year-over-year) revenue to ~1.2 billion British pounds during the first quarter. This rise followed a 13% rise in operating revenue offset by the 6% negative impact of foreign exchange during the quarter.

  • PFE vs. GSK: Which Stock Is the Better Value Option?
    Zacks13 days ago

    PFE vs. GSK: Which Stock Is the Better Value Option?

    PFE vs. GSK: Which Stock Is the Better Value Option?

  • The Quarterly Performances of GlaxoSmithKline’s Business Segments
    Market Realist14 days ago

    The Quarterly Performances of GlaxoSmithKline’s Business Segments

    GlaxoSmithKline’s (GSK) product portfolio is separated into three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. GlaxoSmithKline reported a rise in revenue at constant exchange rates across all three of its segments during the first quarter of 2018 compared to the first quarter of 2017. The Pharmaceuticals segment reported a 4% fall in YoY (year-over-year) revenue to ~4.0 billion British pounds during the first quarter, including a 2% rise in operating revenue offset by the 6% negative impact of foreign exchange.

  • GlaxoSmithKline’s Quarterly Revenue Trend and Estimates
    Market Realist14 days ago

    GlaxoSmithKline’s Quarterly Revenue Trend and Estimates

    GlaxoSmithKline (GSK) reported revenue of ~7.2 billion British pounds in the first quarter, a 2% fall compared to the ~7.3 billion pounds it reported during the first quarter of 2017. Its revenue included a 4% rise in operating revenue, which was more than offset by the 6% negative impact of foreign exchange during the quarter. GlaxoSmithKline reports its revenues under three business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines.

  • GlaxoSmithKline’s Valuation on June 29
    Market Realist14 days ago

    GlaxoSmithKline’s Valuation on June 29

    GlaxoSmithKline (GSK) is a global pharmaceutical company with a focus on sustainable growth through strategizing its business beyond pharmaceuticals. GlaxoSmithKline reports its financial statements in British pounds.

  • New Strong Sell Stocks for July 2nd
    Zacks15 days ago

    New Strong Sell Stocks for July 2nd

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

  • 4 Drug and Biotech Stocks Awaiting FDA Decisions in July
    Zacks15 days ago

    4 Drug and Biotech Stocks Awaiting FDA Decisions in July

    In the first six months of the year, the FDA grants approval to 17 new treatments.

  • Novartis hands investors Alcon spin-off, $5 billion share buyback
    Reuters18 days ago

    Novartis hands investors Alcon spin-off, $5 billion share buyback

    Novartis (NOVN.S) plans to spin off its Alcon eye care business to shareholders and buy back up to $5 billion in stock as Chief Executive Vas Narasimhan refocuses the Swiss group on prescription drugs. Shares in Novartis were up 4.1 percent by 1540 GMT as investors welcomed the news. Alcon, a legacy from former Novartis boss Daniel Vasella's empire building, has been problematic since Novartis bought it for $52 billion in 2011, expanding into implantable lenses for cataract sufferers, surgical devices and contact lenses.

  • Reuters - UK Focus18 days ago

    Novartis hands investors Alcon spin-off, $5 bln share buyback

    Novartis plans to spin off its Alcon eye care business to shareholders and buy back up to $5 billion in stock as Chief Executive Vas Narasimhan refocuses the Swiss group on prescription drugs. Shares (Berlin: DI6.BE - news) in Novartis were up 4.1 percent by 1540 GMT as investors welcomed the news. Alcon, a legacy from former Novartis boss Daniel Vasella's empire building, has been problematic since Novartis bought it for $52 billion in 2011, expanding into implantable lenses for cataract sufferers, surgical devices and contact lenses.

  • Sanofi (SNY) Finalizes Deal for European Generic Unit Sale
    Zacks18 days ago

    Sanofi (SNY) Finalizes Deal for European Generic Unit Sale

    Sanofi (SNY) finalizes sale of its European generic unit, Zentiva, for $2.2 billion.

  • Will a Trade War With China Wreak Havoc in US Healthcare?
    Zacks18 days ago

    Will a Trade War With China Wreak Havoc in US Healthcare?

    It is a known fact that Chinese investments breathe life into small and mid-scale healthcare companies in America.

  • The Wall Street Journal18 days ago

    [$$] Novartis Announces Buyback, Eye-Care Spinoff

    said he sees a rapidly evolving technological landscape in which the company needs to concentrate its capital on using digital technology to drive cutting-edge medicine. Mr. Narasimhan said the spinoff is tax-neutral and the best option for shareholders, who will have the possibility to hold shares in a leading opthalmology medical device company. Alcon had more than $7 billion worth of sales in 2017, Novartis said.

  • A Look at Eli Lilly’s Valuations on June 25
    Market Realist19 days ago

    A Look at Eli Lilly’s Valuations on June 25

    Eli Lilly (LLY) is one of the leading global drug manufacturers, and it operates under two segments—Human Pharmaceuticals and Animal Health Products. Eli Lilly surpassed Wall Street analysts’ estimates for earnings per share and revenues for the first quarter and reported EPS of $1.34 on revenues of $5.7 billion during the quarter.

  • 3 Dividend Stocks That Pay You More Than Verizon Does
    Motley Fool20 days ago

    3 Dividend Stocks That Pay You More Than Verizon Does

    Looking for companies that return big value to shareholders? Verizon checks that box, but these three stocks have it beat.

  • Should You Expect GlaxoSmithkline Pharmaceuticals Limited (NSE:GLAXO) To Continue Delivering An ROE Of 17.05%?
    Simply Wall St.20 days ago

    Should You Expect GlaxoSmithkline Pharmaceuticals Limited (NSE:GLAXO) To Continue Delivering An ROE Of 17.05%?

    This article is intended for those of you who are at the beginning of your investing journey and want to begin learning the link between GlaxoSmithkline Pharmaceuticals Limited (NSE:GLAXO)’s returnRead More...

  • Roche's (RHHBY) Flu Candidate Gets Priority Review by the FDA
    Zacks21 days ago

    Roche's (RHHBY) Flu Candidate Gets Priority Review by the FDA

    Roche's (RHHBY) member Genentech announces that the FDA has accepted a new drug application (NDA) and granted priority review to its baloxavir marboxil to treat patients suffering from influenza A and influenza B.

  • 3 Best Big Pharma Stocks of 2018 So Far
    Motley Fool21 days ago

    3 Best Big Pharma Stocks of 2018 So Far

    Are any of these biggest year-to-date winners smart picks for the long term?

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes